Association of Renal Function and Direct-Acting Antiviral Agents for HCV: A Network Meta-Analysis
| العنوان: | Association of Renal Function and Direct-Acting Antiviral Agents for HCV: A Network Meta-Analysis |
|---|---|
| المؤلفون: | Heng-Cheng Chu, Yu-Shiuan Lin, Te-Chao Fang, Chih-Chin Kao, Yi No Kang, Mai-Szu Wu |
| المصدر: | Journal of Clinical Medicine Volume 7 Issue 10 Journal of Clinical Medicine, Vol 7, Iss 10, p 314 (2018) |
| بيانات النشر: | MDPI, 2018. |
| سنة النشر: | 2018 |
| مصطلحات موضوعية: | hepatitis C virus, medicine.medical_specialty, Anemia, lcsh:Medicine, Renal function, Lower risk, urologic and male genital diseases, Article, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, direct-acting antiviral agents (DAAs), medicine, 030212 general & internal medicine, business.industry, lcsh:R, General Medicine, Hepatitis C, medicine.disease, female genital diseases and pregnancy complications, Discontinuation, Meta-analysis, Relative risk, 030211 gastroenterology & hepatology, business, chronic kidney disease, Kidney disease |
| الوصف: | The effectiveness and safety of direct-acting antiviral agents (DAAs) in hepatitis C virus (HCV) patients with renal insufficiency remain controversial. Therefore, this network meta-analysis aims to assess effectiveness and safety of DAAs in populations with different renal function. The pooled data were obtained from Cochrane Library, EMBASE, PubMed, and Web of Science. Thirteen studies recruited 6884 patients with hepatitis C infection and reported their outcomes in relation to different levels of renal function after treatment with DAAs. The results showed no difference in the virologic responses among patients with different renal function. Regarding safety, whereas in patients without chronic kidney disease (CKD) or with early CKD DAAs were associated with a risk ratio (RR) of 0.14 (95% confidence interval (CI), 0.04 to 0.43) for renal disorder, increased risk of renal function deterioration was found in advanced-CKD patients, though this effect may be related to the natural course of advanced CKD. Similarly, patients without CKD or with early CKD showed a lower risk of anemia (RR, 0.34 95% CI, 0.20 to 0.57) and discontinuation (RR, 0.41 95% CI, 0.39 to 0.56) than patients with advanced CKD. The efficacy of DAAs for HCV treatment was comparable in patients with advanced CKD and in those with early CKD or without CKD. However, the safety of DAAs should be verified in future studies. |
| وصف الملف: | application/pdf |
| اللغة: | English |
| تدمد: | 2077-0383 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d62e407c745aec20fe0a69536b333265Test http://europepmc.org/articles/PMC6210726Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....d62e407c745aec20fe0a69536b333265 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 20770383 |
|---|